Analytical methods for measuring multiple licit and illicit drugs and metabolites in oral fluid require high sensitivity, specificity, and accuracy. With the limited volume available for testing, comprehensive methodology is needed for simultaneous measurement of multiple analytes in a single aliquot. This report describes the validation of a semi-automated method for the simultaneous extraction, identification, and quantitation of 21 analytes in a single oral fluid aliquot. The target compounds included are amphetamine, methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxyamphetamine, 3,4-methylenedioxyethylamphetamine, pseudoephedrine, cocaine, benzoylecgonine, codeine, norcodeine, 6-acetylcodeine, morphine, 6-acetylmorphine, hydrocodone, norhydrocodone, dihydrocodeine, hydromorphone, oxycodone, noroxycodone, oxymorphone, and phencyclidine. Oral fluid specimens were collected with the Intercept ® device and extracted by solid-phase extraction (SPE). Drug recovery from the Intercept device averaged 84.3%, and SPE extraction efficiency averaged 91.2% for the 21 analytes. Drug analysis was performed by liquid chromatography-tandem mass spectrometry in the positive electrospray mode using ratios of qualifying product ions within ±25% of calibration standards. Matrix ion suppression ranged from -57 to 8%. The limit of quantitation ranged from 0.4 to 5 ng/mL using 0.2 mL of diluted oral fluid sample. Application of the method was demonstrated by testing oral fluid specimens from drug abuse treatment patients. Thirty-nine patients tested positive for various combinations of licit and illicit drugs and metabolites. In conclusion, this validated method is suitable for simultaneous measurement of 21 licit and illicit drugs and metabolites in oral fluid.
Introduction
The convenience of oral fluid collection under observed conditions provides a significant advantage over urine in drug testing and monitoring programs (1, 2) . Without observed collections, drug abusers are frequently motivated to "tamper" with their urine specimens by various means such as substitution with clean specimens or fluids resembling urine and by addition of various chemicals that are designed to either destroy drugs present or interfere with their measurement (1) . Drug users also have learned that prior to collection, consumption of excess fluids may successfully dilute drug concentrations in urine to undetectable levels (2) . Although the prevalence of tampering and dilution attempts in various urine testing programs is difficult to establish, it is clear that such techniques are broadly understood among illicit drug users and a variety of commercial products and instructions are available to assist drug users to avoid detection.
The growing popularity of oral fluid testing over the last two decades has been made possible through improvements in screening and confirmation technologies. Oral fluid specimens typically contain drugs and metabolites at considerably lower concentrations than in urine and are limited in volume generally to 1 mL or less. Thresholds for oral fluid are at least 10-fold lower than urine, and methods must be validated to enable reliable detection of recent drug use for the numerous classes of abused drugs (3, 4) . These analytical challenges have been met by use of sensitive screening methods such as ELISA and by confirmation methods such as gas chromatography (GC) and liquid chromatography (LC) coupled with tandem mass spectrometry (MS) (5) .
The requirements for accurate confirmation of multiple drugs and metabolites at low nanogram-per-milliliter concentrations in limited volumes of oral fluid have been addressed by use of various MS techniques. Several reviews have appeared that describe inherent advantages and weaknesses of the technologies for analysis of oral fluid (4, (6) (7) (8) . Early confirmation methods for oral fluid analysis for drugs of abuse were generally based on GC-MS and tandem GC-MS analysis (5, (9) (10) (11) . More recently, LC-MS-MS has emerged as a preferred method of analysis obviating the need for the production of thermally stable volatile analytes required by GC-MS methods. Enhanced oxycodone-d 6 , phencyclidine-d 5 , hydrocodone-d 6 , MDA-d 5 , oxymorphone-d 3 , dihydrocodeine-d 6 , norhydrocodone-d 3 , noroxycodone-d 3 , and pseudoephedrine-d 3 were purchased from Cerilliant (Round Rock, TX). One-milliliter ampoules in acetonitrile of either 100 µg/mL or 1 mg/mL of cocaine-d 3 , 6-acetylmorphine, 6-acetylcodeine, and cocaine were also purchased from Cerilliant. 6-Acetylcodeine-d 6 was purchased from Lipomed (Cambridge, MA). Ibuprofen, medazapam, naproxen, norchlordiazepoxide, and procaine were purchased from Alltech (Nicholasville, KY). Loperamide, penicillin, quinidine, quinine, and tolmetin were purchased from Sigma Aldrich.
Extraction solutions consisting of 50:50 methanol/water (v/v) solution and 78:20:2 methylene chloride/isopropanol/ ammonium hydroxide (v/v/v) solutions were prepared daily. A solution of 50 mM phosphoric acid was prepared using HPLCgrade phosphoric acid (85%) in deionized water. 1% HCl (v/v) was prepared in HPLC-grade methanol. HPLC-grade methanol (10%) in HPLC-grade water (v/v) was prepared fresh for each run.
Specimens
Collection of oral fluid with the Intercept collection device (OraSure Technologies) was performed according to manufacturer's instructions. Briefly, the Intercept collection device consists of a treated absorbent cotton fiber pad affixed to a plastic stick and is packaged with a preservative solution (0.8 mL) in a plastic container. The Intercept collection device collects oral fluid with expected mean volumes of 0.4 mL (14) . Because of the possible range of oral fluid volumes collected, concentrations are reported in this study without correction for dilution. Typically, approximately 0.4 mL of oral fluid is collected on the collection device pad which results in a 1:3 dilution when placed in the preservative solution. Authentic oral fluid specimens were collected under a protocol approved by Institutional Review Board (IRB) review from drug treatment subjects at the Addiction Research Testing Center, Division of Medical Services, Research and Information Technology (New York, NY). Two oral fluid specimens were collected simultaneously (one on each side of the mouth). All specimens were coded and contained no confidential information about participants. Upon completion of collection, specimens were shipped to OraSure Technologies for processing. The specimens were centrifuged at 1500 × g for 10 min to recover the diluted oral fluid specimen in 16.8 × 67-mm Sarstedt (Numbrecht, Germany) polypropylene tubes. Each pair of simultaneously collected specimens was processed by combining the specimens in a single container with mixing to ensure adequate volume for testing. From this point on, the specimens were maintained at 2-8°C.
Negative specimens were collected using the Intercept collection device from five volunteers to determine percent recovery from the collector, SPE recovery, and to test for matrix effects during LC-MS-MS analysis.
Specimen preparation
Specimens were prepared for extraction by addition of 3.8 mL of 50 mM phosphoric acid to a 13 × 100-mm glass culture tube. Internal standards and a 200-µL aliquot of sample were added to each corresponding tube. To blanks, 200 µL of oral fluid diluent was added in place of the specimen. To prepare the calibration curve, calibration standards in methanol corresponding in concentrations to 1-, 2-, 8-, and 16-times cutoff concentrations of each analyte were added along with 200 µL of oral fluid diluent. Table I lists the cutoff concentrations for each analyte, internal standards, and their respective concentrations. An unextracted sample tube was prepared by adding internal standard to elution solvent in a 12 × 75-mm glass culture tube and set aside until after extraction. The tubes were then vortex mixed.
Specimen solutions were then extracted on the Caliper Life Sciences (Hopkinton, MA) RapidTrace SPE workstation using Varian SPEC DAU 30-mg SPE columns (Lake Forrest, CA). The SPE columns were conditioned with 0.5 mL of ACSgrade methanol, then loaded with the 4 mL of diluted sample at 2 mL/min. The columns were rinsed sequentially with deionized water, 50 mM phosphoric acid, 50:50 methanol/DI water, methanol, and methylene chloride, all at a flow rate of 12 mL/min. The columns were dried for 2 min and eluted with 1 mL methylene chloride/ isopropanol/ammonium hydroxide (78:20:2) at 0.5 mL/min. After elution, 100 µL of 1% hydrochloric acid in HPLC-grade methanol was added to each tube to prevent the loss of amphetamines and then dried under nitrogen at 5-15 psi. The extracts were reconstituted with 200 µL of 10% HPLC-grade methanol in HPLC-grade water and transferred to autosampler vials with inserts and capped for analysis. Before starting another extraction series, the RapidTrace SPE Workstation was rinsed with methanol and water to minimize carryover.
Chromatographic conditions
Chromatography was performed with an Agilent (Santa Clara, CA) model 1100 HPLC system using a Restek (State College, PA) Allure PFP Propyl LC column (50 × 2.1 mm, 5 µm) with gradient elution. The mobile phases were 0.1% formic acid, 2 mM ammonium acetate, and 2% acetonitrile in HPLC-grade water (A) and 0.1% formic acid, 2 mM ammonium acetate, and 10% HPLC-grade water in acetonitrile (B). The column temperature was maintained at 30°C. The injection volume was 20 µL, and the flow rate through the column was 800 μL/min. The mobile phase gradient was as follows: autosampler load 1 min, equilibration at 90% A for 0.5 min, ramp to 65% A over 1.5 min, hold at 65% A for 2 min, ramp to 5% A in 1 min, ramp to 2% A in 1 min, hold at 2% A for 2 min, then rapidly ramp back to 90% A, and re-equilibrate for 3 min for a total time of 12 min per sample. The vial wash option was used for the Agilent 1100 HPLC autosampler to minimize carryover by rinsing of the autosampler needle in a vial containing 50:50 methanol/water.
MS
Detection was performed on an API 3200 tandem MS operating in positive electrospray mode (ESI) (MDS SCIEX, Toronto, ON, Canada). The optimum conditions were as follows: curtain gas, 50 psi; collision-activated dissociation, 5 psi; heated nebulizer temperature, 600°C; nebulizing gas, 50 psi; and heater gas, 60 psi.
In order to establish the appropriate multiple reaction monitoring (MRM) conditions for individual compounds, solutions of standards (Table I) in methanol/water (50:50, v/v) were infused into the MS, and the declustering potential (DP) and collision energy (CE) were optimized for the different ions. Data acquisition, peak integration, and calculation were interfaced to a computer workstation running the Analyst 1.5 software. The precursor ions, the corresponding product ions, retention times, and DP and CE for the drugs, metabolites, and their deuterated analogues are listed in Table II .
Each analysis required the ratio between the quantitation and qualification product ion to be within ±25% of that established by the average response of the four calibration standards used each run. This ion ratio as well as a retention time within ±2% of the average of the four calibration standards were required to meet criterion for a positive result for each analyte.
Method Validation Linearity and interassay precision
Quantitation was performed by integration of the area under the specific MRM chromatogram peak in reference to the integrated area of the corresponding deuterated analogue. Freshly prepared oral fluid calibrators were generated by spiking oral fluid diluent with methanolic standards at con- centrations equaling 1-, 2-, 8-, and 16-times cutoff concentrations. Linearity was calculated by plotting peak-area ratios using linear regression and forcing zero, using 1/x weighting with Analyst version 1.5 software from Applied Biosysytems. Linear response and LC-MS-MS carryover were assessed by running spiked oral fluid diluent samples with methanolic standards from 32-fold to 512-fold cutoff concentrations with extracted blanks between each of these samples. The assay was considered linear if the quantitative response was within 20% of the target range for the compound. Carryover was noted when the extracted blank after the standard was greater than the concentration of the limit of quantitation (LOQ) for that analyte. Interassay precision was determined by running the low and high controls (±25%) and elevated controls in 10 different runs. These controls were prepared by spiking oral fluid diluent with methanolic standards at the start of the validation process and storing these spiked controls at 2-8°C for the duration of the validation, which was approximately 3 months. 
Limit of detection (LOD) and LOQ
The LOD and the LOQ were administratively defined at 20% and 40% of cutoff concentrations, respectively. The LOD and LOQ were tested in triplicate over three separate runs by spiking oral fluid diluent with methanolic standards to achieve these concentrations. The average percent accuracy and percent CV of the LOD and LOQ controls were calculated across three runs. The LOD and LOQ both required the ion ratio to be present within the ±25% range that was established for each analyte as well as the retention time to be within ±2% of the average of the retention time of the four calibration standards.
Recovery and matrix effects
To test for recovery and matrix effects, negative specimens were collected from five drug-free volunteers using the Intercept collection device. The specimens were centrifuged at 1500 × g for 10 min. Oral fluid specimens with final concentrations of twofold cutoff concentration (PRE) and negative oral fluid (POST) specimens were prepared from the five volunteer collections. The negative specimens were spiked to a twofold cutoff concentration after extraction and before being dried under nitrogen. Five unextracted samples were also prepared with a twofold cutoff concentration. The percent recovery was calculated with the equation PRE × 100. The ----POST percent matrix effect was calculated with the equation ( POST -1 ) × 100. These equations were based on the __________ Unextracted study by Chambers et al. (18) .
Collection device recovery
For the study of drug recovery from the Intercept collection device, oral fluid specimens were collected from five volunteers by expectoration into plastic tubes. Half of the specimen from each volunteer was spiked to a 12-fold cutoff concentration with each analyte. For each specimen, 400 μL of the spiked oral fluid was added to an Intercept pad and 400 µL of matching negative oral fluid was added to a second Intercept pad. The pads were stored overnight at room temperature in 0.8 mL of preservative in the Intercept collection device. The next day, the devices were centrifuged at 1500 × g for 10 min. The matching negative Intercept specimens were then spiked at fourfold cutoff concentrations to account for the threefold dilution of the spiked oral fluid specimens. The specimens were analyzed, and the percent recovery from the device was determined for each analyte. 
Selectivity
To determine selectivity, 10,000 ng/mL of clonazepam, cotinine, dextromethorphan, diphenhydramine, doxepin, gemfibrozil, hydroxyalprazolam, ibuprofen, imipramine, lidocaine, loperamide, medazapam, naproxen, norchlordiazepoxide, nortriptyline, penicillin, pentobarbital, phenobarbital, procaine, THC, quinidine, quinine, theophyline, tolmetin, cocaethylene, morphine-3β-D-glucuronide, nalorphine, phentermine, and phenylpropanolamine were added to a series of +25% controls. The controls were then analyzed and the results were evaluated for deviations in concentration greater than 20% of target concentration as well as ion ratios exceeding acceptable ranges.
Interferences due to common foods and beverages
A series of products were evaluated to test for possible interferences from common foods and beverages that may be present in residual amounts in the oral cavity. Orange juice, cranberry juice, antiseptic mouthwash, cough syrup, cola, coffee, tea, baking soda, toothpaste, sugar, and hydrogen peroxide were added directly to +25% control samples to determine if there was any interference with identification (ion ratio effects) or quantitation. The solid materials were prepared in water at a concentration of 100 mg/mL. Twenty microliters of each solution was then added to 200 µL of +25% controls. The controls were then evaluated for deviations greater than 20% of target concentration as well as ion ratios exceeding acceptable ranges.
Results and Discussion
Calibrators, controls, and stability Calibration curves were prepared daily for each analytical batch. The calibrator samples contained all analytes over the range of 1-to 16-times that of the cutoff concentrations. These calibrators generated the quantitative data as well as defined the ion ratio (±25%) and retention time (±2%) acceptance criteria. Low (-25%), high (+25%), and elevated quality control samples were included in each batch to determine batch acceptability.
The ±25% as well as the elevated quality control samples were stored at 2-8°C, were analyzed periodically over the duration of the study (3 months). There was no significant change in the control concentration for any of the analytes during this period of time.
Method validation
The method was validated for precision, accuracy, sensitivity, specificity, linearity, and recovery in compliance with international guidance (19) . A representative chromatogram of an extracted calibrator sample containing the 21 analytes at cutoff concentrations is shown in Figure 1 . Analysis of extracts of individual analytes (one analyte and its deuterated analogue) showed no interferences in other MRM channels. The cutoff concentrations utilized in this method (Table I) , with the exception of the amphetamines and the synthetic opiates and their metabolites, when adjusted for buffer dilution are consistent with the cutoff concentrations reported by Cone et al. (11) and are similar, with the exception of phencyclidine, to the confirmatory test cutoff concentrations proposed by SAMHSA (17) . Cutoff concentrations for the synthetic opiates and their metabolites were established at values equal to morphine and codeine (10 ng/mL), except for 6-acetylmorphine (1 ng/mL) and 6-acetylcodeine (5 ng/mL).
Precision and accuracy were determined across a range of concentrations. Data were collected over 10 separate runs for each analyte. The interassay precision for the controls at ±25% of the cutoff concentrations ranged from 4.6 to 19.1% (Table  III) . Accuracy ranged from 98.2 to 124.8%. The signal-to-noise (S/N) ratio of the quantifying ion and the qualifying ion (cutoff control sample) for each analyte is also listed in Table III . The signal to noise was measured by the LC-MS operating system software (Analyst 1.5). The lowest S/N for any of the ions at the cutoff concentration was the qualification ion for norcodeine which was 77 at 10 ng/mL. The highest S/N was the 6-acetylcodeine quantitation ion which was 1380 at 5 ng/mL. However, its qualification ion had a S/N of 174.
Precision and accuracy of LOD and LOQ control samples are listed in Table IV . The LOD and LOQ concentrations were administratively established at 0.2 and 0.4 times the cutoff concentrations with the exception of 6-acetylmorphine. For 6-acetylmorphine, the LOQ and the cutoff were both 1 ng/mL and the LOD was 0.4 ng/mL. CVs for the LOD samples ranged from 0.7 to 29.4%, and accuracy ranged from 85.3 to 120.0%. Relative to LODs, the range of CVs for the LOQ samples were lower and ranged from 1.2 to 17.8%, and the accuracy ranged from 78.8 to 118.4%. Oxycodone and oxymorphone were the only two analytes to have % CVs greater than 15% for both the LOD and LOQ. However, these %CVs were still under 20%. Considering that both LOD and LOQ specimens were required to meet both retention time and ion ratio criteria, it became apparent that the LOD samples demonstrated sufficient precision and accuracy to qualify as the LOQ for all compounds other than 6-acetylmorphine. This observation was supported by the strong S/N ratios demonstrated for each analyte at its respective cutoff concentration (Table III) .
Precision and accuracy of elevated (highly concentrated) control samples are listed in Table V . The %CVs for the elevated quality control sample, which was in most cases at 200 times the cutoff concentration, ranged from 5.0 to 19.2% (Table V) . The 6-AM elevated control concentration was 30 ng/mL because of the limited linearity for this compound. Table V also lists the upper limit of linearity (ULOL) and carryover limits for the analytes. For most analytes, the ULOL was at least 100 times the cutoff concentration. The only exception was 6-AM, which was only linear to 30 ng/mL. Carryover was determined by running extracted blanks between each calibrator from a concentration of 30 times the cutoff concentration to a concentration of 500 times the cutoff to determine the concentration at which carryover occurred. This procedure analyzed the total carryover, including contribution by the RapidTrace SPE workstation as well as that contributed by the LC-MS-MS. There were only three compounds, MDEA, cocaine, and PCP, that demonstrated carryover limits below the established upper linear range. Specimens that exceeded the ULOL or carryover limit were diluted and reanalyzed.
Percent recovery of drug/metabolites from the Intercept oral fluid collection device, extraction recovery, and matrix effects are listed in Table VI . Recovery from the device averaged 84.3% for all analytes with the lowest recovery being 73% for hydromorphone. The SPE recovery averaged 91.2% and exceeded 84% for all analytes. The largest matrix effect was observed for PCP at -57%. The amphetamines, cocaine, and benzoylecgonine had matrix effects of about -25%. Nine opiates (oxycodone, dihydrocodeine, norcodeine, morphine, codeine, 6-AM, hydrocodone, oxymorphone, and hydromorphone) had matrix effects within ±10%. There were only three compounds that shared the same internal standard in this method. All others had their own matching deuterated internal standard that helped mask any potential matrix effects. The three compounds that shared the same internal standard were codeine, norcodeine, and dihydrocodeine. Deuterated (d 3 ) dihydrocodeine was selected for these opiates due to the similar retention time between the three compounds. There was no deuterated internal standard available for norcodeine, and dihydrocodeine interfered with the deuterated (d 3 ) codeine internal standard, so the deuterated codeine internal standard was eliminated from the method.
The only compound, of the 29 tested for specificity, that produced an interference problem was phentermine in the analysis of methamphetamine. When 10,000 ng of phentermine was added to the +25% control, the quantification ion for methamphetamine was increased resulting in failed ion ratio criterion. Of the 11 food and beverage products added directly to the +25% control material prior to extraction, none interfered with quantitative accuracy or ion ratios of the analytes.
Authentic specimens
The validated method was applied to the analysis of 73 oral fluid specimens collected with the Intercept device from patients in a drug treatment center with IRB approval. The patient specimens were also stored at 2-8°C Table VII . No amphetamines were detected in this group of patient specimens. Twenty-six (35.6%) patients were positive for cocaine or benzoylecgonine. An additional four patients were positive for cocaine and/or benzoylecgonine at concentrations ≥ LOQ. There were nine patients that tested positive in various combinations of "opiate" derivatives (morphine, codeine, 6-acetylmorphine, and 6-acetylcodeine). All nine of these opiate positives were positive for 6-acetylmorphine, and three of these patients were positive only for 6-acetylmorphine in the range of 1.1 to 7.7 ng/mL. Only one patient was positive for 6-acetylcodeine at 28.9 ng/mL. This same patient had a 6-acetylmorphine concentration of 435 ng/mL, the highest 6-acetylmorphine concentration observed in this population. One patient was positive for hydrocodone and its metabolites, norhydrocodone and hydrocodol (dihydrocodeine). Three patients were positive for oxycodone, and all three had concentrations of noroxycodone above the LOD (2 ng/mL) of the method ranging from 2.4 to 25.2 ng/mL. Four patients (5.5%) were positive for phencyclidine in the range of 4.0-45.3 ng/mL.
Conclusions
A comprehensive assay for sensitive detection and measurement of 21 licit and illicit drugs and metabolites has been described that is suitable for testing a small volume aliquot of oral fluid. The method was validated for linearity, accuracy, precision, specificity, sensitivity, and recovery. The method was successfully applied to analysis of oral fluid specimens obtained from patients in drug abuse treatment.
